An interventional study of take blood samples in Celiac Disease, sponsored by Meir Medical Center. Status unknown. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-29.
Sponsored by Meir Medical Center · Not applicable, Interventional, and Basic science
Celiac disease is an autoimmune process that causes destructive changes in the epithel of the small bowel and it is also a pre-malignant state (e.g lymphoma). The aim of the study is to examine telomere length and other parameters of genetic instability from peripheral blood lymphocytes of patients with celiac disease compared with healthy controls.
339 studies on the registry are indexed under Celiac Disease; 80 are open to participants now.
This study's planned enrollment of 40 is below the median of 50 across 207 interventional studies indexed under Celiac Disease.
Browse Celiac Disease studies →Meir Medical Center is the lead sponsor of 400 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: take blood samples
telomere length
Time frame: at entry, after 6 months of gluten-free diet
No study locations are listed for this record.
This study is status unknown, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.